Bosh sahifaAMGN • NASDAQ
add
Amgen
276,39 $
Seans yopilganidan keyin:(0,33%)+0,90
277,29 $
Yopilgan:12-sen, 19:47:15 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
282,73 $
Kunlik diapazon
276,07 $ - 282,94 $
Yillik diapazon
253,30 $ - 339,17 $
Bozor kapitalizatsiyasi
148,80 mlrd USD
Oʻrtacha hajm
2,12 mln
Narx/foyda
22,61
Dividend daromadliligi
3,44%
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 9,18 mlrd | 9,43% |
Joriy xarajat | 3,50 mlrd | 12,82% |
Sof foyda | 1,43 mlrd | 91,96% |
Sof foyda marjasi | 15,60 | 75,48% |
Har bir ulushga tushum | 6,02 | 21,13% |
EBITDA | 4,34 mlrd | 5,79% |
Amaldagi soliq stavkasi | 8,67% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 8,03 mlrd | -13,69% |
Jami aktivlari | 87,90 mlrd | -3,31% |
Jami passivlari | 80,47 mlrd | -5,31% |
Umumiy kapital | 7,43 mlrd | — |
Tarqatilgan aksiyalar | 538,36 mln | — |
Narxi/balansdagi bahosi | 20,49 | — |
Aktivlardan daromad | 8,47% | — |
Kapitaldan daromad | 11,81% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 1,43 mlrd | 91,96% |
Operatsiyalardan naqd pul | 2,28 mlrd | -7,28% |
Sarmoyadan naqd pul | -389,00 mln | -79,26% |
Moliyadan naqd pul | -2,67 mlrd | -0,91% |
Naqd pulning sof oʻzgarishi | -782,00 mln | -92,14% |
Boʻsh pul | 220,75 mln | -92,64% |
Haqida
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Tashkil etilgan
8-apr, 1980
Sayt
Xodimlar soni
28 000
